Economy/Home · Economy

[Breaking] SK Biopharmaceuticals Signs 63.3 Billion Won U.S. Supply Contract for Epilepsy Drug cenobamate... 9% of Revenue

SK Biopharmaceuticals has signed a supply contract for the sale of cenobamate, its new drug for treating epilepsy, in the U.S. market. The counterparty is its U.S. subsidiary, SK Life Science, Inc., and SK Biopharmaceuticals disclosed this fact on the 23rd. The contract amount is 63,305,392,934 won

Oseong Kwon
Staff Reporter
2 min read
[Breaking] SK Biopharmaceuticals Signs 63.3 Billion Won U.S. Supply Contract for Epilepsy Drug cenobamate... 9% of Revenue
CBC News

SK Biopharmaceuticals has signed a supply contract for the sale of cenobamate, its new drug for treating epilepsy, in the U.S. market. The counterparty is its U.S. subsidiary, SK Life Science, Inc., and SK Biopharmaceuticals disclosed this fact on the 23rd.

The contract amount is 63,305,392,934 won. This figure was calculated by applying the exchange rate of 1,360 won per dollar—the rate as of the contract date (September 23)—to the total contract value of USD 46,548,083.04, with no separate value-added tax. In terms of scale, this contract amounts to 9.0% of the company's 2025 consolidated revenue (706,740,960,308 won).

The contract period runs from September 23 to September 25. The sales and supply location is to be designated by SK Life Science, Inc., and there is no contract deposit or advance payment. Payment is due within 120 days of delivery.

Meanwhile, SK Biopharmaceuticals stated that since this contract is an internal transaction supplying products to its U.S. subsidiary, it will not be reflected in consolidated financial statement revenue. The contract date is based on the approval date of the Purchase Order.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.